Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02806687
Other study ID # RC31/13/7046
Secondary ID 2016-000572-20
Status Completed
Phase Phase 2
First received
Last updated
Start date January 30, 2017
Est. completion date June 30, 2022

Study information

Verified date March 2023
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pancreatic ductal adenocarcinoma (PDAC) is the fifth leading cause of cancer-related death in Western countries, and its incidence has increased over the last 40 years. Curative surgery to manage PDAC is possible in only a fraction of patients; indeed, a vast majority (85%) of patients is diagnosed with locally advanced tumors and/or metastases because they lack specific symptoms and early markers for this disease. For these patients, palliative armamentarium consists of conventional chemotherapeutic agents such as Gemcitabine and, more recently, FOLFIRINOX, which offer marginal survival benefits. Consequently, the prognosis for PDAC is still very poor and there is great need for new treatments that can change this poor outcome. In this context, the investigators have devised, in the past few years, a highly innovative approach based on therapeutic gene transfer, which does not rely on a specific genetic and/or cellular background to inhibit PDAC tumor growth. the investigators found that SSTR2 and DCK::UMK gene transfer demonstrated complementary therapeutic effects to inhibit tumor progression and dissemination, and reduced tumor burden, respectively. On the basis of these promising preclinical data, the investigators conducted past three years the first clinical study of non-viral vector-mediated therapeutic gene delivery, guided by endoscopy (EUS), and combined with standard Gemcitabine therapy in patients with locally advanced and metastatic PDAC. The phase 1 demonstrated that the gene-therapy product CYL-02 is expressed in PDAC tumors (with long-lasting expression within tumor tissues), is distributed within the bloodstream in some extent, when combined with Gemcitabine it can inhibit primary-tumor progression and dissemination. Our results tend to demonstrate therapeutic efficacy, especially in patients with locally advanced tumors. Based on these encouraging results, the investigators propose that patients with locally advanced PDAC at the time of diagnosis may clinically benefit from this approach. This phase II study is designed to compare the efficacy of intra-tumoral gene delivery of CYL-02 plus Gemcitabine treatment or Gemcitabine alone in patient with locally advanced PDAC.


Description:

Pancreatic adenocarcinoma is the fifth leading cause of cancer related deaths in Western countries. The sole curative treatment is surgical resection. Unfortunately, curative surgery is possible in only 10 to 15 % of cases. In a palliative way, the remaining patients can be treated with chemotherapy in locally advanced (Gemcitabine) or metastatic (FOLFIRINOX) tumors. These treatments ameliorate some clinical parameters but modestly the median survival. There is an urgent need in novel treatment and gene therapy is one of these innovative approaches. The investigators demonstrated that SST2 gene (that codes for somatostatin receptor subtype 2) when transferred in pancreatic experimental tumours significantly decreases tumor progression and exerts an anti-metastatic effect. SST2 gene transfer also induced a local bystander effect due to antiproliferative, pro-apoptotic and anti-angiogenic actions. SST2 gene transfer also sensitizes pancreatic tumors to the therapeutic effect of Gemcitabine. In order to improve this chemosensitization the investigators added the DCK::UMK gene, which is a fusion between two cDNAs each coding enzymes that are critical for Gemcitabine intracellular metabolism. Effect of DCK::UMK gene transfer in combination of Gemcitabine treatment dramatically reduced the size of primary tumours in experimental models of pancreatic cancer. Finally, combining SST2 and DCK::UMK gene transfer using a single expression plasmid intratumorally injected, the investigators obtained a significant "regression" of experimental primary pancreatic tumors (Patent Cayla-INSERM 2010). In collaboration with Invivogen company, this proof of concept led us to set up a pilot Phase I clinical trial of gene therapy in unresectable pancreatic cancer patients. For this phase I gene therapy trial (THERGAP-01NCT01274455 Dec. 2010 - Sept. 2012), the investigators produced a gene therapy product (CYL-02) in GMP grade (plasmid encoding for SST2 and DCK::UMK genes complexed to a non-viral synthetic vector PolyEthyleneImine 22 kDa). The protocol was based on two Endoscopic Ultrasound (EUS)-guided direct intratumoral injections (at one month interval) of increasing doses of DNA (125 to 1000 µg) followed by Gemcitabine infusions within 2 months. After inclusion of 22 unresectable pancreatic cancer patients the investigators demonstrated the excellent feasibility of this protocol whatever the localization of the tumor and previous treatment. No serious adverse events directly imputable to the experimental product occurred. There was no major diffusion of CYL-02 in blood (none in urine) while transgene was detected and expressed in tumour tissues in a dose-dependent manner at one month post-injection (maximum at dose 1000µg - DNA + mRNA). Primary tumor was reduced in size at one month and remained stable at 2 months with no metastatic progression in the subgroup of locally advanced patients in whom median progression-free survival and overall survival were respectively of 6.4 and 12.6 months. These results tend to demonstrate a therapeutic effect and lead to this randomized open multicenter phase 2 trial comparing the therapeutic effect of the association "intratumoral delivery of the gene therapy product CYL-02 plus gemcitabine" versus "gemcitabine alone" in patients with locally advanced non metastatic unresectable/untreated patients. The primary objective is to compare the effect of each modality of treatment on the progression free survival. The secondary objectives are to compare the effect on overall survival, to evaluate the antitumor response, Quality of Life local and general tolerance. For the 6 french centers the investigators plan to include 100 patients (18 months for inclusion, 12 months for duration of the trial for each patient) with proven locally advanced non metastatic untreated pancreatic adenocarcinoma, 50 patients in each Arm: Arm A: two EUS-guided injections of CYL-02 (dose 1000 µg) at one month interval in combination of Gemcitabine infusion 1000 mg/m2 every week within two months followed by 4 months (or until progression) of Gemcitabine (same dose and rhythm); Arm B: Gemcitabine alone 1000 mg/m2 within 6 months (or until progression). In each Arm patients will be subjected to clinical and imaging follow up after 6 months including or not other treatments. CYL-02 compound will be produced and supply by DBI/Eurofins and financed by Invivogen company. This clinical trial will be accompanied by an independent monitoring committee, which will review safety data and provide recommendations to the Sponsor regarding the safety of subjects, the conduct of the study and potential premature termination. Evaluation will be made upon clinical symptoms, signs of tumor progression, EUS in Arm A (at one month), CT-Scan, at 2, 4, 6, 9 and 12 months (ARM A and B, RECIST 1.1 criteria). Quality of Life every month (EORTC QLC-C30 questionnaire), local and general tolerance and Pharmacokinetics of CYL-02 will be also assessed. The dose of 1000 µg will be used and corresponds to the maximal dose tested during the phase 1b (Thergap-1). This dose demonstrated a long lasting expression within tumor, a good antitumor effect and a good tolerance (buscail et al, mol her 2015).


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically proven local advanced pancreatic adenocarcinoma patients, - Non metastatic locally advanced non resectable CP assessed after multidisciplinary staff* and/or surgery, - Patient without metastasis, - No previous antitumor treatment or pancreatic resection, - OMS status = 2, - Measurable tumor according RECIST criteria v 1.1, - Patient that give their informed consent, - Patient older than 18 years of age, - Patients no contraindication of general anaesthesia, - Patient with primary pancreatic tumour accessible to EUS (no digestive stenosis or stomach resection). (*: at least oncologist, radiologist, digestive surgeon and gastroenterologist) Exclusion Criteria: - Patients with metastatic pancreatic tumors disease, - Contraindication of Gemcitabine infusion, - Non-measurable primary tumour (less than 2 cm in size), - Borderline tumour according, - Tumour eligible to a possible neo-adjuvant treatment by radio-chemotherapy or chemotherapy (after multidisciplinary staff*), - Contraindication to EUS-guided fine needle aspiration biopsy (coagulation disorders), - Patient in exclusion period or participating in another clinical research protocol, - Patient that cannot understand or read the information form / consent or is not being able to take the decision to participate to the study, - Pregnant woman, or of childbearing potential not using contraception, - Patient under judicial protection, guardianship or curatorship, - Patient with cystic tumor or pancreatic pseudocyst, - Patient bearing solid tumors other than adenocarcinoma of the pancreas (endocrine tumor, metastasis), - Granulocytopenia: granulocytes <1000/mm3, - Thrombocytopenia: platelet count <100 000/mm3, - Patient not effectively treated for malignant jaundice (biliary stent or bypass) if present at diagnosis. (*: at least oncologist, radiologist, digestive surgeon and gastroenterologist)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gene Therapy product CYL-02
Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine. Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression).
Gemcitabine
Gemcitabine alone 3 weeks/month during 6 months (or until progression).

Locations

Country Name City State
France APHP Hôpital Beaujon Clichy
France Hôpital privé Jean Mermoz Lyon
France CHU de Marseille Hôpital Nord Marseille
France Institut Paoli Calmettes Marseille
France Institut régional du Cancer Montpellier
France Rangueil Hospital Toulouse
France Institut Gustave Roussy Villejuif

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Toulouse BIOTHERAPY department of the clinical center of investigation- CIC 1436, Toulouse, InvivoGen Therapeutics

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival Progression free-survival (PFS) is defined as the time interval between the date of the beginning of the treatment (Arm A: first injection of CYL-02; Arm B: first injection of Gemcitabine) and the date of local or regional progression or metastases progression or occurrence of distant metastases (including liver or non-liver metastases) or occurrence of 2nd pancreatic cancer or death (all causes), whichever occurs first. Patients alive and free of all these events will be censored at the last follow-up. Other events will be ignored (EJC 2014 Bonnetain et al). From date to randomization until the date of first documented progression or date of death, whichever came first, assessed up to 12 months.
Secondary Overall survival Overall survival will be calculate from the date of the beginning of the treatment (Arm A: first injection of CYL-02; Arm B: first injection of Gemcitabine) until the date of death. Up to 1 year
Secondary Tumor response Tumor response rates will be determined by post-therapy EUS for patients from Arm A (maximal diameter of primary tumor at 1 months versus baseline) and CT scans (Thoraco-abdominal CT - RECIST criteria 1.1 at 2, 4, 6 months versus baseline) for all patients. The overall rates for objective response (complete plus partial responses) and stable disease (no progression within 3 months) will be also considered. Difference between baseline and months 1, 2, 4, 6 and 12 months.
Secondary Quality of life change Score of Quality Of Life according to the EORTC QLQ-C30 Difference between baseline and month 12.
Secondary Biological tumoral marker Dosage of CA 19-9 levels Difference between baseline and month 12
Secondary Incidence of treatment-emergent adverse events Adverse Events, Serious Adverse Events Up to 12 months
Secondary Biodistribution Only for patient from Toulouse center: quantification of the transgene by qPCR in blood sample and tumor biopsy before and after transgene injection. Month 1
Secondary Peak plasma concentration (Cmax) Only for patient from Toulouse center: quantification of the transgene by qPCR in blood sample and tumor biopsy before and after transgene injection. Month 1
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Completed NCT01959672 - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT03673423 - Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Not yet recruiting NCT06026943 - Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer N/A
Completed NCT03054987 - Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction N/A
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02072616 - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Phase 3
Completed NCT02174887 - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer Phase 1
Recruiting NCT03703063 - Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer Phase 1
Terminated NCT04077372 - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers N/A
Recruiting NCT03073785 - Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer Phase 2
Completed NCT03665441 - Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Phase 3
Recruiting NCT04627246 - Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer Phase 1
Not yet recruiting NCT06217666 - Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC) Phase 1
Recruiting NCT05585320 - A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04119362 - PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
Completed NCT03105921 - Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma N/A